에서 실시간으로 운영 중이에요! 자세히 알아보기

Ascentage Pharma

AAPG

시가총액 US$14.4억

15.37 USD

+0.68

4.63%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

1일

4.63%

5일

1.18%

1개월

-0.19%

3개월

-24.66%

6개월

-43.41%

연초 이후

-41.71%

1년

-57.84%

5년

-11.57%

10년

-11.57%

소개: Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.

직원 수: 828

건강관리 생명공학

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 30.8%

중립 69.2%

부정적 0%

Ascentage Pharma Stock Could More Than Double: Analyst

Ascentage Pharma Group International (NASDAQ:AAPG) stock could see significant upside as the cancer drug developer approaches several major clinical trial results in 2027, according to William Blair.

Ascentage Pharma Stock Could More Than Double: Analyst

3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead

Small-cap stocks tend to fly under the radar. Often in startup stages, these companies can lack analyst coverage, be overlooked by institutional investors, and be illiquid due to low average trading volume.

3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead

3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight

Small-cap companies are accustomed to living in the shadow of mega-cap tech firms, but there are signs that the market backdrop could be changing for some of these companies. Investors have been looking beyond the Magnificent Seven for growth opportunities, and smaller companies with improving fundamentals, unique business models, or other noteworthy catalysts may finally have an opportunity to win investor attention.

3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight

Ascentage Pharma to Participate in Four Upcoming Investor Conferences

ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management will participate in four upcoming investor conferences in New York, New York.

Ascentage Pharma to Participate in Four Upcoming Investor Conferences

Ascentage Pharma Group International (AAPG) Q2 2026 Earnings Call Transcript

Ascentage Pharma Group International (AAPG) Q2 2026 Earnings Call Transcript

Ascentage Pharma Group International (AAPG) Q2 2026 Earnings Call Transcript

Ascentage Pharma Group International H1 Earnings Call Highlights

Ascentage Pharma Group International NASDAQ: AAPG reported first-half 2026 revenue growth as it continued investing in global registrational studies for its hematology-oncology pipeline and began building commercial capabilities outside China.

Ascentage Pharma Group International H1 Earnings Call Highlights

Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates

Revenue for the first half of 2026 increased 29% year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr.

Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates

Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit

ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management will participate in the Evercore ISI 2nd Annual China Biotech Summit, being held August 17-19, 2026 at The Ritz-Carlton Shanghai, Pudong.

Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit

CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026

In a release issued under the same headline earlier today by Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), please note that in the first paragraph of the release, the time should be 7:00 am Eastern Daylight Time (EDT) on August 19, 2026 / 7:00 pm Hong Kong Time (HKT) and not 9 am EDT and 9 pm HKT as previously stated. The corrected release follows:

CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026

Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026

ROCKVILLE, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that it will release its six months 2026 unaudited interim results and provide business updates at 9:00 am Eastern Daylight Time (EDT) on August 19, 2026 / 9:00 pm Hong Kong Time (HKT) on August 19, 2026.

Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.